Guggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) to $210.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

UBS Downgrades Salix Pharmaceuticals (SLXP) to NeutralFebruary 24, 2015 7:22 AM Valeant Pharma (VRX) to Acquire Salix Pharma (SLXP) in $14.5B DealFebruary 22, 2015 4:29 PM Valeant Pharma (VRX) Nears Deal for Salix Pharma (SLXP) - CNBC's FaberFebruary 20, 2015 9:46 AM